< Back to previous page

Project

Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases (FIBROTARGET)

Despite the advances in treating inflammation, no medical treatments have managed to decline fibrostenosis incidence in Crohn’s disease. Consequently, surgical resection remains irreversible in more than 70% of cases. FIBROTARGET will help reducing the burden of fibrosis by disclosing and validating novel targetable cellular mechanisms that are pivotal in the evolution towards fibrosis and will develop new in vitro/in vivo models to study fibrosis pathogenesis in inflammatory bowel diseases (IBD). Moreover, we will identify the specific gene signature as the biomarker to maximize patient stratification, revolutionizing the timely detection of patients with risk of intestinal fibrosis, and the future performance evaluation of novel antifibrotic treatments. FIBROTARGET will build and validate a new imaging pipeline to detect and manage fibrosis in IBD patients by using CE- and EMA/FDA-cleared non-invasive MRE technologies and discussions with regulators will allow the use of these tools in drug development.
Date:15 Feb 2023 →  Today
Keywords:Fibrosis, inflammatory bowel disease, Crohn's disease
Disciplines:Gastro-enterology